Acute respiratory distress syndrome patients improve with experimental monoclonal antibody treatment

Doctors have few options for patients who develop a life-threatening lung condition called acute respiratory distress syndrome, or ARDS.

A frequent cause of death during the COVID-19 pandemic, ARDS occurs when an inflammatory cascade triggered by infection or injury leaks fluid into the lungs, crashing blood oxygen levels.

Nearly 40% of people affected die. ...